North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CHIlled Platelet Study "CHIPS"
NCT04834414
Recruiting
A phase 3 randomized partial blind storage duration ranging study in patients undergoing complex cardiac surgery that will compare the transfusion of cold stored platelets to standard room temperature stored platelets. The primary objective is to establish that cold stored platelets have a non-inferiority (or superiority) to room temperature platelets.
Gender:
ALL
Ages:
Between 0 days and 84 years
Trial Updated:
03/03/2025
Locations: Wake Forest, Winston-Salem, North Carolina
Conditions: Acute Blood Loss
Register for Updates
Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity
NCT03890614
Recruiting
The objective of this project is to compare chemosensitivity between chemotherapy combinations in bone marrow aspirates using 3D organoid models. The investigators overarching hypothesis is that 3D organoids are ideal to test chemosensitivity in real time, to provide personalized medicine and guidance in the setting of relapsed hematologic malignancy and potentially other cancers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Hematologic Malignancy
Register for Updates
WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy
NCT03824652
Recruiting
This is a randomized control trial testing the effect of walnut supplementation on prostate cancer progression in 50 men with biopsy confirmed prostate cancer and planning to undergo RP. Patients consented to the study will be randomly assigned to either continue their usual diets (control arm) or to the walnut arm for 4-10 weeks depending on the window between their consent date and the date for RP.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Durham VA Medical Center, Durham, North Carolina
Conditions: Prostate Cancer
Register for Updates
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
NCT02235857
Recruiting
Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/03/2025
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
NCT06780306
Recruiting
The purpose of this randomized, controlled, multicenter study is to evaluate the safety and efficacy of TTAX03 in participants with mild to moderate DED. The primary question it aims to answer is if TTAX03 is safe. The secondary is the effectiveness. Researchers will compare 10mg of TTAX03 reconstituted in 150, 300, or 600 uL saline to the saline control group to look at effectiveness. Participants will be randomized to a treatment group one time and be evaluated at 5 different study visits.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Wilmington Eye at Brunswick Forest, Leland, North Carolina
Conditions: Dry Eye, Dry Eye Disease (DED), Dry Eye Disease With Severe Keratitis
Register for Updates
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults with Soft Tissue Sarcomas (INVINCIBLE-3)
NCT06263231
Recruiting
To compare Overall Survival (OS) for INT230-6 vs United States (US) Standard of Care (SOC) in participants with unresectable or metastatic liposarcoma, undifferentiated pleomorphic sarcoma or leiomyosarcoma who have disease progression prior to study enrollment following no more than 2 standard therapies, which must have included an anthracycline-based regimen, unless contraindicated, and then a maximum of 1 additional regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Sarcoma,Soft Tissue
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Levine Cancer Institute/ Atrium Health, Charlotte, North Carolina
Conditions: H3 K27M, Glioma
Register for Updates
Innovations in Genicular Outcomes Registry
NCT05495334
Recruiting
The registry will capture prospective data on patients receiving pain management for chronic pain due to knee osteoarthritis (OA) or pain optimization for knee arthroplasty due to knee OA. The OA pain therapies may include cryo nerve block, radiofrequency ablation (RFA), intra-articular (IA) corticosteroids, viscosupplementation, opioids, and others (e.g., non-steroidal anti-inflammatory drugs \[NSAIDs\]).
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Blue Nine Systems, Asheville, North Carolina
Conditions: Knee Osteoarthritis
Register for Updates
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613
Recruiting
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
02/28/2025
Locations: UNC Children's Research Institute, Chapel Hill, North Carolina
Conditions: Mucopolysaccharidosis II
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2025
Locations: The Neurological Institute PA, Charlotte, North Carolina
Conditions: Relapsing Multiple Sclerosis
Register for Updates
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
NCT04919226
Recruiting
The purpose of the study is to evaluate the efficacy, safety \& patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Duke University School of Medicine, Duke Cancer Institute, Durham, North Carolina
Conditions: Neuroendocrine Tumors
Register for Updates
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013
Recruiting
The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.
Gender:
ALL
Ages:
All
Trial Updated:
02/28/2025
Locations: Duke Children's Hospital, Durham, North Carolina
Conditions: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Register for Updates